Taxotere™ is a chemotherapy drug used for the treatment of breast cancer. One study that analyzed the effects of Taxotere™ found that up to 9.2% of women treated with the drug experience PERMANENT hair loss. Although hair loss is very common with many chemotherapy agents used to treat breast cancer, PERMANENT hair loss should not occur.
9.2% of Women who take Taxotere™ experience permanent hair loss.
The Company has not added any adequate warnings to the Taxotere™ prescribing information in the United States.
What You Need to Know
The manufacturer of Taxotere™, Sanofi-Aventis, bears the responsibility for warning women who choose to use the drug to treat their breast cancer that Taxotere™ has a high risk of causing permanent hair loss. Despite this responsibility, the company has not added any adequate warning to the Taxotere™ prescribing information in the United States that warns about this serious risk. However, years ago, the company added warnings about permanent hair loss to the Taxotere™ prescribing information in some foreign countries.
The physical and emotional pain that women with breast cancer endure throughout their treatment is severe on its own. Adding the emotional trauma of permanent hair loss resulting from Taxotere™ use can be devastating. Women who have suffered from such an experience should be heavily compensated for their loss.
We are Here to Help
The lawyers at PBC are currently evaluating the potential claims of women who have been treated for breast cancer with Taxotere™ and experienced permanent hair loss. PBC will file Taxotere™ lawsuits against the manufacturer of the drug on behalf of women who have suffered permanent hair loss as a result of using the drug. If you or a loved one has suffered permanent hair loss as a result of chemotherapy treatment involving Taxotere™, please contact Pendley, Baudin & Coffin to have your case confidentially evaluated.
